Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

BAFF Antibody

Tabalumab, LY2127399

Tags: cancer signaling, hematologic cancer, phase II

BAFF Antibody Derived from Dal Porto JM, et al1; Kurosaki T, et al2; Mackay F and Schneider P.3

Target

B cell activating factor (BAFF) is a member of the tumor necrosis factor (TNF) family and has been shown to be an important survival factor for peripheral B cells. It is expressed as a membrane-bound type II transmembrane protein that can be cleaved from the membrane, generating a soluble protein fragment.3 BAFF has been implicated in conferring a survival advantage to B cell malignancies, such as multiple myeloma.4

Molecule

Tabalumab (LY2127399) is a fully human monoclonal antibody designed to have neutralizing activity against both membrane-bound and soluble BAFF.5

Clinical Development

Tabalumab is being investigated in a clinical trial in patients with multiple myeloma.

[NCT01602224]    Hematologic Cancer    A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)